- Home
- Â /Â Corcept Therapeutics
Corcept Therapeutics
Stock Price
$48.2
2024-10-29
Market Capitalization
$5 B
2024-10-29
Revenue
$482.4 M
FY, 2023
Corcept Therapeutics Summary
Company Summary
- Overview
- Corcept Therapeutics is a company that specializes in the research and development of cortisol modulators. It focuses on modulating cortisol activity at the glucocorticoid receptor (GR).
- Type
- Public
- Status
- Active
- Founded
- 1998
- HQ
- Redwood City, CA, US | view all locations
- Website
- https://corcept.com/
- Cybersecurity rating
- ESG rating
Table of Contents
Key People
Hazel Hunt, Chief Scientific Officer
Joseph Belanoff, Chief Executive Officer, President and Director
Amy Flood, Chief Human Resources, Communications Officer
Corcept Therapeutics Financials
Summary Financials
- Revenue (Q3, 2024)
- $182.5M
- Gross profit (Q3, 2024)
- $179.7M
- Net income (Q3, 2024)
- $47.2M
- Cash (Q3, 2024)
- $137.3M
- EBIT (Q3, 2024)
- $46.6M
- Enterprise value
- $4.9B